An expert explains the importance of genetic testing in metastatic colorectal cancer, as recent FDA approval highlights its ...
This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...
A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...
Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...
A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly ...
Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...
A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...
Hosted on MSN24d
Silexion reports breakthrough in KRAS cancer therapyThe drug is designed to inhibit several oncogenic KRAS mutations, which are prevalent in various human cancers. Mitchell Shirvan, Ph.D., Chief Scientific Officer of Silexion, expressed enthusiasm ...
Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback